According to California-based VC firm Menlo Ventures’ 2026 State of AI in Healthcare report, released earlier this week, healthcare should be the place to be if you’re an AI start-up.
In the US, which is the biggest global AI market, healthcare AI was the largest vertical AI market by far in 2026, growing a whopping 2.5 times to $5.5 billion and leaving the next biggest vertical, legal, in the dust (see chart below).
A good chunk of that was AI drug discovery, but clinical AI – the sort that local start-up champions Heidi and Lyrebird are chasing – is still larger by itself than the next vertical market.
But big isn’t always beautiful. Big means competitive, and the US AI healthcare market is currently in a state of hyper competition.
Six weeks after raising AUD $500 million in investment and debt funding, Heidi Health has cut about 18% of its staff and lost two of its three cofounders.
CEO Dr Tom Kelly says the company was “too optimistic” about how quickly large health systems would buy. His main problem was that big market above, the US. And customers buying wasn’t the biggest issue.



